Talphera Q3 net loss narrows, beats expectations
TLPH•Talphera’s third-quarter net loss was $4.02 million, beating the $4.35 million analyst estimate, while its $4.14 million operating loss also beat expectations. The company is seeking FDA feedback on ending NEPHRO CRRT study enrollment by Dec. 31, 2026, and raised its estimated peak sales for nafamostat in CRRT to more than $200 million.
1. Quarterly results
Talphera reported a third-quarter net loss of $4.02 million, compared with an analyst consensus estimate of $4.35 million. Its operating loss was $4.14 million, versus an expected $4.22 million loss.
2. Study and sales outlook
The company is seeking FDA feedback on closing enrollment in its NEPHRO CRRT study as of Dec. 31, 2026, citing slow recruitment and fewer qualifying patients at clinical sites. Talphera said current enrollment exceeds 80% power for the primary endpoint and raised its estimated peak sales for nafamostat in CRRT to more than $200 million.
3. Higher expenses
Higher research and development and selling, general and administrative expenses in the quarter were primarily due to increased Niyad development activities and pre-launch commercial preparation.
